Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients

Daniel W. Hommer, Theodore P. Zahn, David Pickar, Daniel P. van Kammen

Research output: Contribution to journalArticle

Abstract

The specific α1-noradrenergic antagonist, prazosin, was administered to seven schizophrenic patients in a double-blind, placebo-controlled trial. Patients showed no change in any of their psychiatric symptoms as rated by nurses on global depression and psychosis scales and by physicians on the Brief Psychiatric Rating Scale. However, they did show a significant increase in autonomic arousal as measured by changes in skin conductance. The increased autonomic arousal is probably mediated by increases in plasma norepinephrine induced by chronic prazosin treatment.

Original languageEnglish (US)
Pages (from-to)193-204
Number of pages12
JournalPsychiatry Research
Volume11
Issue number3
DOIs
StatePublished - 1984
Externally publishedYes

Fingerprint

Prazosin
Arousal
Brief Psychiatric Rating Scale
Psychotic Disorders
Psychiatry
Norepinephrine
Nurses
Placebos
Depression
Physicians
Skin
Therapeutics

Keywords

  • autonomic arousal
  • norepinephrine
  • prazosin
  • Schizophrenia
  • skin conductance
  • α-receptors

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients. / Hommer, Daniel W.; Zahn, Theodore P.; Pickar, David; van Kammen, Daniel P.

In: Psychiatry Research, Vol. 11, No. 3, 1984, p. 193-204.

Research output: Contribution to journalArticle

Hommer, Daniel W. ; Zahn, Theodore P. ; Pickar, David ; van Kammen, Daniel P. / Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients. In: Psychiatry Research. 1984 ; Vol. 11, No. 3. pp. 193-204.
@article{2988b1371fbc4fb69f09fac18db748a9,
title = "Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients",
abstract = "The specific α1-noradrenergic antagonist, prazosin, was administered to seven schizophrenic patients in a double-blind, placebo-controlled trial. Patients showed no change in any of their psychiatric symptoms as rated by nurses on global depression and psychosis scales and by physicians on the Brief Psychiatric Rating Scale. However, they did show a significant increase in autonomic arousal as measured by changes in skin conductance. The increased autonomic arousal is probably mediated by increases in plasma norepinephrine induced by chronic prazosin treatment.",
keywords = "autonomic arousal, norepinephrine, prazosin, Schizophrenia, skin conductance, α-receptors",
author = "Hommer, {Daniel W.} and Zahn, {Theodore P.} and David Pickar and {van Kammen}, {Daniel P.}",
year = "1984",
doi = "10.1016/0165-1781(84)90068-4",
language = "English (US)",
volume = "11",
pages = "193--204",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients

AU - Hommer, Daniel W.

AU - Zahn, Theodore P.

AU - Pickar, David

AU - van Kammen, Daniel P.

PY - 1984

Y1 - 1984

N2 - The specific α1-noradrenergic antagonist, prazosin, was administered to seven schizophrenic patients in a double-blind, placebo-controlled trial. Patients showed no change in any of their psychiatric symptoms as rated by nurses on global depression and psychosis scales and by physicians on the Brief Psychiatric Rating Scale. However, they did show a significant increase in autonomic arousal as measured by changes in skin conductance. The increased autonomic arousal is probably mediated by increases in plasma norepinephrine induced by chronic prazosin treatment.

AB - The specific α1-noradrenergic antagonist, prazosin, was administered to seven schizophrenic patients in a double-blind, placebo-controlled trial. Patients showed no change in any of their psychiatric symptoms as rated by nurses on global depression and psychosis scales and by physicians on the Brief Psychiatric Rating Scale. However, they did show a significant increase in autonomic arousal as measured by changes in skin conductance. The increased autonomic arousal is probably mediated by increases in plasma norepinephrine induced by chronic prazosin treatment.

KW - autonomic arousal

KW - norepinephrine

KW - prazosin

KW - Schizophrenia

KW - skin conductance

KW - α-receptors

UR - http://www.scopus.com/inward/record.url?scp=0021166288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021166288&partnerID=8YFLogxK

U2 - 10.1016/0165-1781(84)90068-4

DO - 10.1016/0165-1781(84)90068-4

M3 - Article

C2 - 6145176

AN - SCOPUS:0021166288

VL - 11

SP - 193

EP - 204

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 3

ER -